Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Presented At:
LabRoots - Drug Discovery Virtual Event 2019
Presented By:
Jagath Reddy Junutula, PhD - Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
Speaker Biography:
Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs.
Webinar:
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Webinar Abstract:
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different immune checkpoint modulators).
Learning Objectives:
1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
2. Presentation will also highlight key factors that influence in developing next generation ADCs.
Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/drug-discovery-2019)
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/drug-discovery-2019)
3. Click Here to get your PACE (Expiration date – February 27, 2021 03:00 PM) – https://www.labroots.com/credit/pace-credits/3307/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates канала Labroots
LabRoots - Drug Discovery Virtual Event 2019
Presented By:
Jagath Reddy Junutula, PhD - Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
Speaker Biography:
Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs.
Webinar:
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Webinar Abstract:
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different immune checkpoint modulators).
Learning Objectives:
1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
2. Presentation will also highlight key factors that influence in developing next generation ADCs.
Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/drug-discovery-2019)
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/drug-discovery-2019)
3. Click Here to get your PACE (Expiration date – February 27, 2021 03:00 PM) – https://www.labroots.com/credit/pace-credits/3307/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates канала Labroots
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
What are Antibody-drug Conjugates (ADCs)?A Clinician's Perspective on Cancer Drug DevelopmentQualitative and Quantitative Bio-analysis of Antibody Drug Conjugates (ADCs) using Mass SpectrometryAntibody-drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenge PresentationDesigning siRNAs for improving their therapeutic applicationsModulating Tumor-Associated MacrophageWorking with antigen-specific T cellsLecture: Antibody Drug Conjugates — State of the Art, Trends, Challenges, Zaki SellamCancer Metabolism: From molecules to medicineWhy Blue Whales Don't Get Cancer - Peto's ParadoxPreventing cell misidentification in your daily lab routineHow do monoclonal antibodies work? Rituximab, infliximab, adalimumab and othersCurrent Upfront Management of DLBCLIntroduction to Module 6: Drug Discovery and DevelopmentUnderstanding Pharmaceutical industry by Kris Kristensen | Webinar | Technology | Starweaver |How to use CRISPR Cas9 for knockout, knock in and gene activationRecent advances for simultaneous analysis to determine embryo PGT-A and PGT-M status with NGSNew antibodies and antibody-drug conjugates for B-cell lymphomaTargeting prostate cancer stem cells with T cell immunotherapyMonoclonal antibodies in medicine